Santhanam Sundar

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

Nicholas D. James, Matthew R. Sydes, Noel W. Clarke et al. · The Lancet · 2015 · 1.9K citations · Full text

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

Eugene D. Kwon, Charles G. Drake, H. I. Scher et al. · The Lancet Oncology · 2014 · 1.5K citations · Full text

Urology, Oncology, Docetaxel Chemotherapy +9

Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial

Cora N. Sternberg, Iwona Skoneczna, J. Martijn Kerst et al. · The Lancet Oncology · 2014 · 381 citations

Radical Cystectomy, Urology, Surgical Oncology +7

Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol

Matthew R. Sydes, Melissa Spears, Malcolm D. Mason et al. · Annals of Oncology · 2018 · 240 citations · Full text

Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991

M. Bolla, P. Maingon, C. Carrié et al. · Journal of Clinical Oncology · 2016 · 211 citations · Full text